Efficacy and Safety of Accell Evo3 Demineralized Bone Matrix (DBM) in Instrumented Posterolateral Lumbar Spine Fusion

NCT ID: NCT01430299

Last Updated: 2018-06-07

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

43 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-06-30

Study Completion Date

2016-10-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for posterolateral spine fusion with a retrospective comparison to a historical patient cohort.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The objective of this study is to prospectively evaluate the performance of Integra Accell Evo3 Demineralized Bone Matrix as an adjunct for posterolateral spine fusion with a retrospective comparison to a historical patient cohort. The historical patient cohort has not been previously published and therefore, no reference to this group can be provided.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stenosis Spondylosis Degenerative Changes

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Demineralized Bone Matrix

a prospective cohort of patients undergoing posterolateral lumbar fusion with Evo3 in the posterolateral space

Group Type OTHER

Demineralized Bone Matrix

Intervention Type DEVICE

Accell Evo3 in posteriolateral fusion (prospective cohort)

rh-BMP2

A retrospective cohort of patients who were age- and sex- matched to the prospective cohort who underwent posterolateral lumbar fusion with use of rh-BMP2

Group Type OTHER

rh-BMP2

Intervention Type DEVICE

rh-BMP2 in posterolateral fusion (retrospective cohort)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Demineralized Bone Matrix

Accell Evo3 in posteriolateral fusion (prospective cohort)

Intervention Type DEVICE

rh-BMP2

rh-BMP2 in posterolateral fusion (retrospective cohort)

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Accell Evo3 Infuse

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years of age or older at the time of surgery
* Require spinal fusion using posterior Transforaminal Lumbar Interbody Fusion (TLIF), Posterolateral Fusion (PLF) or Posterior Lumber Interbody Fusion (PLIF) in 1 to 3 levels between L3-S1
* Follow-up radiographic imaging post surgery

Exclusion Criteria

* Long term users of medications known to inhibit fusion,bone metabolism or epidural steroid injections
* Immunosuppressive agents, Disease Modifying Anti-rheumatic drugs (DMARDs) or any similar immunomodulating drugs, Growth Factors or Insulin
* Treated with radiotherapy since their surgery
* Medical conditions known to impact bone metabolism, such as Paget's disease, osteoporosis
* Pregnant or lactating women or women wishing to become pregnant
* Prisoner
* Participating in an investigational drug or another device study
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

SeaSpine, Inc.

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Eric Klineberg, M.D.

Role: PRINCIPAL_INVESTIGATOR

University of CA - Davis

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of CA-Davis, Dept. of Orthopaedics, Adult & Pediatric Spine Surgery

Sacramento, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

ACC3-US-2010-1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

LUMBAR & SACROILIAC FUSION STUDY
NCT07204288 RECRUITING NA
Natural Matrix Protein
NCT07217964 ENROLLING_BY_INVITATION
Anterior Gen Plus Study
NCT04629807 UNKNOWN NA